Vertex Revenue Per Share from 2010 to 2025

VRTX Stock  USD 428.11  0.00  0.00%   
Vertex Pharmaceuticals Revenue Per Share yearly trend continues to be fairly stable with very little volatility. Revenue Per Share is likely to outpace its year average in 2025. Revenue Per Share is the amount of revenue generated by Vertex Pharmaceuticals per share of stock, calculated by dividing total revenue by the average number of shares outstanding. View All Fundamentals
 
Revenue Per Share  
First Reported
2010-12-31
Previous Quarter
34.47
Current Value
36.19
Quarterly Volatility
13.68822331
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Vertex Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vertex Pharmaceuticals' main balance sheet or income statement drivers, such as Total Revenue of 11.9 B, Gross Profit of 10.4 B or Other Operating Expenses of 7.3 B, as well as many indicators such as Price To Sales Ratio of 23.42, Dividend Yield of 0.0 or PTB Ratio of 7.46. Vertex financial statements analysis is a perfect complement when working with Vertex Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Vertex Pharmaceuticals Correlation against competitors.
For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.

Latest Vertex Pharmaceuticals' Revenue Per Share Growth Pattern

Below is the plot of the Revenue Per Share of Vertex Pharmaceuticals over the last few years. It is the amount of revenue generated by a company per share of stock, calculated by dividing total revenue by the average number of shares outstanding. Vertex Pharmaceuticals' Revenue Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vertex Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 41.18510 Years Trend
Slightly volatile
   Revenue Per Share   
       Timeline  

Vertex Revenue Per Share Regression Statistics

Arithmetic Mean16.79
Geometric Mean9.86
Coefficient Of Variation81.51
Mean Deviation12.04
Median11.98
Standard Deviation13.69
Sample Variance187.37
Range38.1207
R-Value0.93
Mean Square Error26.35
R-Squared0.87
Slope2.68
Total Sum of Squares2,811

Vertex Revenue Per Share History

2025 36.19
2024 34.47
2023 38.3
2022 34.87
2021 29.39
2020 23.88
2019 16.21

About Vertex Pharmaceuticals Financial Statements

Vertex Pharmaceuticals investors use historical fundamental indicators, such as Vertex Pharmaceuticals' Revenue Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Vertex Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Revenue Per Share 34.47  36.19 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Vertex Stock Analysis

When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.